Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103

Aug. 31, 2022 4:40 AM ETSorrento Therapeutics, Inc. (SRNE), SCLXBy: Ravikash, SA News Editor2 Comments

Headquarters of US Food and Drug Administration (FDA)


  • The U.S. Food and Drug Administration (FDA) granted fast track designation to Scilex's drug/device product candidate SP-103 to treat acute low back pain (LBP).
  • Scilex — which is over 99.9% owned by Sorrento Therapeutics (NASDAQ:SRNE) — is developing SP-103 to be a non-opioid triple-strength, non-aqueous lidocaine topical system for acute LBP.
  • "We are very pleased that the FDA has granted Fast Track designation for the non-opioid SP-103 program, the next generation triple strength formulation of ZTlido," said Scilex President and CEO Jaisim Shah.
  • If approved, SP-103 could become the first FDA-approved lidocaine topical product to treat acute LBP, Scilex said in an Aug. 30 press release.
  • Scilex is currently in the middle of a merger with SPAC Vickers Vantage I (NASDAQ:VCKA) and will go public on Nasdaq under the symbol SCLX.
  • SRNE +13.40% to $2.20 premarket Aug. 31

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.